{
  "docId": "019dd923-5f69-752d-a9b8-7335d4e4bbbd",
  "docSlug": "UazyKuUCi7yVVPL3wJds",
  "documentTitle": "See the pitch deck that Compass Pathways used to raise $80 million and fuel its rise into one of the world's biggest psychedelics companies",
  "authorId": "Pitchdecks",
  "authorName": "Compass Pathways",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.333,
  "pageNumber": 17,
  "pageCount": 28,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 10,
  "notes": "Uses a classic 'market sizing funnel' approach (Patients x % x Cost = TAM).",
  "elementsJson": [
    "headline_text",
    "action_title",
    "process_diagram",
    "callout_box",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5f69-752d-a9b8-7335d4e4bbbd/17",
  "deckHref": "/decks/019dd923-5f69-752d-a9b8-7335d4e4bbbd",
  "deckJsonHref": "/decks/019dd923-5f69-752d-a9b8-7335d4e4bbbd.json",
  "deckAnchorHref": "/decks/019dd923-5f69-752d-a9b8-7335d4e4bbbd#slide-17",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "The unmet medical need in treatment-resistant depression offers massive revenue potential for psilocybin therapy.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-a290-75b0-a21a-2ce7e245ffb0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.5,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Depressed Patients (78m) x Addressable TRD (18-26%) x Direct Medical Cost (£10-15k) = Total Addressable Market (£140-200b)",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a64ac3ac-d3ec-4d73-b5af-7ae62bc2b43c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "disclaimer",
      "text": "* BMS = Bristol-Myers Squibb; CBT = Cognitive Behavioural Therapy; MDD = Major Depressive Disorder. 1-4 footnotes.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eb5cc052-23bb-4f8d-9ecd-62c712eeccff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "TAM: £140-200b",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-a290-75b0-a21a-3016a79b25aa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: NIMH STAR*D study (2006); WHO; Medical journals; EvaluatePharma; BTIG Analyst Report (2017); Oanda.com; COMPASS",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dc620945-a036-482a-8488-ee28e5b77305",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.25,
        "x": 0.7,
        "y": 0.15
      },
      "kind": "table",
      "text": "Revenues from relevant treatments: Esketamine £1.5b, Zoloft £1.8b, Cymbalta £3.3b, Abilify £5.2b, CBT >£5.3b",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ad06d190-69e3-4b3b-8784-4440646e205a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "Addressable Market: The unmet medical need in treatment-resistant depression offers massive revenue potential for psilocybin therapy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "33d06be8-0a53-4ca0-ad5d-00ae1ada7cde",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "market-sizing-funnel",
      "slug": null,
      "matchId": "226aab47-8dd0-4dda-a00b-26ec4e2b6e47",
      "evidence": "Calculation of TAM using patient population, penetration rate, and average cost per patient.",
      "confidence": 0.95
    }
  ],
  "arcBeats": [
    {
      "to": 17,
      "from": 10,
      "beatId": "1b24f627-5397-46d5-a3ed-637425948073",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 10 through 17 present psilocybin therapy as a solution, detailing its value proposition, development program, and market potential.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}